Anixa Biosciences, Inc..
ANIX.US | Research and experimental development on natural sciences and engineering
Anixa Biosciences, Inc. is a biotechnology company focused on the treatment and prevention of cancer. The company is developing novel therapies and vaccines that harness the body's immune system to fight cancer cells. Its therapeutic programs include a novel approach to treating ovarian cancer and a...Show More
Better Health for All
40
Anixa Biosciences' entire business is devoted to developing therapies and vaccines for critical unmet needs in oncology and infectious diseases, including ovarian cancer, triple-negative breast cancer, and anti-viral drug candidates for COVID-19.
1
The company's R&D budget is entirely allocated to health improvement, developing novel CAR-T technology and preventative cancer vaccines for various cancers.
2
The company's preventative vaccines aim to reduce cancer incidence, generating positive health externalities.
3
Anixa also prioritizes preventative health, developing vaccines against breast and ovarian cancer, and exploring additional cancer vaccines for lung, colon, and prostate cancers.
4
The company demonstrates perfect risk transparency, with SEC filings (10-K) detailing numerous risks associated with its operations and drug development.
5
Clinical trials are conducted with strong ethical standards, including FDA and IRB authorization, informed consent, and a focus on patient safety and well-being.
6
The company focuses on triple-negative breast cancer, the most lethal form, and ovarian cancer, which has a low survival rate, demonstrating a commitment to vulnerable populations.
7
Early-phase clinical trials for CAR-T therapy and breast cancer vaccine have shown excellent safety, with no dose-limiting toxicities or severe adverse effects reported.
8
Dr. Sanjay Juneja, a member of Anixa's Cancer Business Advisory Board, is an active international keynote speaker on collaborative and democratized education, and Anixa aims to educate the cancer community.
9
Fair Money & Economic Opportunity
0
Anixa Biosciences, Inc. is a biotechnology company focused on the treatment and prevention of cancer, developing therapies and vaccines. Its core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, customer finance data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, customer debt burden ratio, geographic inclusion for financial services, and financial product simplicity, are not applicable to its business model.
Fair Pay & Worker Respect
50
The company's employee engagement score is 5/5 stars.
1
As of October 31, 2024, Anixa Biosciences, Inc. had five full-time employees.
2
The company offers an Employee Stock Purchase Plan (ESPP) allowing eligible employees to purchase shares at not less than 85% of market value.
3
During the six months ended April 30, 2025, employees purchased 1,518 shares through the ESPP with aggregate proceeds of $4,000.
4
Stock-based compensation expense for employees and directors was $1,993,000 for the six months ended April 30, 2025.
5
The company maintains stock equity incentive plans for employees, directors, and consultants, and has a Code of Business Conduct and Ethics that includes sections on discrimination and harassment.
6
Fair Trade & Ethical Sourcing
0
Anixa Biosciences, Inc. is a biotechnology company focused on research and development, clinical trials, and commercialization of cancer therapies and vaccines. Its business model does not involve the procurement or trade of physical commodities typically associated with fair trade certifications.
1
No other specific, concrete data points were found in the provided articles for any other KPIs related to fair trade and ethical sourcing, such as supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for supplier violations, ethical clauses in supplier contracts, the share of high-risk materials in its spend, or supplier diversity initiatives.
2
Honest & Fair Business
-50
The company has whistleblower protections, and its Code of Business Conduct and Ethics explicitly prohibits retaliatory action against employees who report suspected wrongdoing related to various fraud laws and SEC rules.
1
However, there is no evidence of a secure hotline, training, or independent investigation processes, which maps to a basic policy with low trust. The company also has an anti-corruption policy that prohibits giving anything of value to foreign government officials in compliance with the U.S. Foreign Corrupt Practices Act and addresses gratuities to U.S. government personnel.
2
However, the evidence does not provide details on clear guidance for facilitation payments or gift thresholds, nor does it mention training frequency or effectiveness metrics.
Kind to Animals
-50
Anixa Biosciences has initiated animal testing for two proprietary compounds for Covid-19 therapeutics and plans comprehensive animal studies in anticipation of human clinical trials.
1
The company has also previously conducted animal studies for its breast and ovarian cancer vaccine technologies, with publications in 2016 and 2017.
2
For early-stage research, the company utilizes in silico screening for billions of compounds and in vitro studies for dozens of compounds prior to animal testing.
3
Two compounds are currently undergoing animal testing.
4
Anixa Biosciences is collaborating with OntoChem GmbH on medicinal chemistry for these compounds.
5
No War, No Weapons
0
Anixa Biosciences, Inc. is a biotechnology company focused on cancer treatment and prevention.
1
Its core business activities, such as developing cancer therapies and vaccines, are not directly related to arms manufacturing, military contracts, or conflict facilitation.
2
Consequently, most 'No War, No Weapons' KPIs are not applicable to the company's operations.
3
However, the Phase 1 clinical trial for Anixa's breast cancer vaccine was funded by a grant from the U.S. Department of Defense.
4
While the exact percentage of revenue derived from this grant is not specified, its existence represents an association with a defense entity, indicating minor defense-adjacent services rather than 0% direct arms revenue.
5
Planet-Friendly Business
-20
In 2023, Anixa Biosciences sourced 22% of its operational energy consumption from renewables.
1
Respect for Cultures & Communities
0
No information regarding Anixa Biosciences, Inc.'s engagement with local or indigenous communities, cultural impact assessments, community partnerships, local employment ratios, grievance mechanisms for community concerns, or any other metrics related to 'Respect for Cultures & Communities' was found in the provided articles. The articles primarily focus on clinical trial data, personnel appointments, and carbon footprint.
Safe & Smart Tech
0
The company states that no personal information is shared, indicating strong preventative measures against unauthorized data use.
1
It also reports that there have been no cybersecurity threats that have materially affected the company to date.
2
The company provides annual training to stakeholders on cyber awareness and computing hygiene.
3
Anixa Biosciences is subject to and complies with applicable regulations, including FDA regulations, current good clinical practices (cGCPs), and current good manufacturing practices (cGMPs.
4
The company reviews System and Organization Controls 1 (SOC 1 Type II) certifications from key third-party partners annually.
5
The company maintains a neutral stance on digital rights issues.
Zero Waste & Sustainable Products
-20
Anixa Biosciences has achieved 42% progress in single-use plastic elimination.
1
The company also demonstrates a focus on hazardous waste management, with a 35% reduction in chemical waste minimization and 53% of chemical waste neutralized.
2